Advertisement

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Dec
03
Today In Oncology
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Image-Only AI Model Outperforms Breast Density for 5-Year Breast Cancer Risk Stratification
Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo